Modus's Intended IPO to Spur Sickle Cell Drug R&D
The first IPO for a pharmaceutical company nurtured by Karolinska Development is expected to involve Modus Therapeutics, which has changed its name from Dilaforette and is pursuing the development of a Phase II potential sickle cell therapy.
You may also be interested in...
Novartis has exercised its option to acquire Selexys in a deal worth up to $665m, following data from the Phase II SUSTAIN trial of SelG1 in sickle cell disease. The move follows several recent failures in the space.
Shares in Mast Therapeutics dropped by more than 80% upon news that a Phase III trial of its lead product vepoloxamer in sickle cell disease had failed.
PGLG's application only has one Phase III trial, and Emmaus is hoping statistical re-analyses can address FDA skepticism about clinical meaningfulness of the primary endpoint data.